140 related articles for article (PubMed ID: 8168990)
1. Interleukin-6 serum levels in patients with gynecological tumors.
Scambia G; Testa U; Panici PB; Martucci R; Foti E; Petrini M; Amoroso M; Masciullo V; Peschle C; Mancuso S
Int J Cancer; 1994 May; 57(3):318-23. PubMed ID: 8168990
[TBL] [Abstract][Full Text] [Related]
2. Serum tumor markers in the management of ovarian, endometrial and cervical cancer.
Gadducci A; Cosio S; Carpi A; Nicolini A; Genazzani AR
Biomed Pharmacother; 2004 Jan; 58(1):24-38. PubMed ID: 14739059
[TBL] [Abstract][Full Text] [Related]
3. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer.
Plante M; Rubin SC; Wong GY; Federici MG; Finstad CL; Gastl GA
Cancer; 1994 Apr; 73(7):1882-8. PubMed ID: 8137215
[TBL] [Abstract][Full Text] [Related]
5. Serum evaluation of P53 protein in patients with gynaecological cancer.
Barbati A; Mariani L; Porpora MG; Anceschi M; Collini P; Lauro V; Cosmi EV
Anticancer Res; 2000; 20(2A):1033-5. PubMed ID: 10810393
[TBL] [Abstract][Full Text] [Related]
6. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer.
Moradi MM; Carson LF; Weinberg B; Haney AF; Twiggs LB; Ramakrishnan S
Cancer; 1993 Oct; 72(8):2433-40. PubMed ID: 8402460
[TBL] [Abstract][Full Text] [Related]
7. Normalization of abnormal plasma amino acid profile-based indexes in patients with gynecological malignant tumors after curative treatment.
Suzuki Y; Tokinaga-Uchiyama A; Mizushima T; Maruyama Y; Mogami T; Shikata N; Ikeda A; Yamamoto H; Miyagi E
BMC Cancer; 2018 Oct; 18(1):973. PubMed ID: 30314462
[TBL] [Abstract][Full Text] [Related]
8. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer.
Bellone S; Watts K; Cane' S; Palmieri M; Cannon MJ; Burnett A; Roman JJ; Pecorelli S; Santin AD
Gynecol Oncol; 2005 Jul; 98(1):92-8. PubMed ID: 15904949
[TBL] [Abstract][Full Text] [Related]
9. Is thrombocytosis a valid indicator of advanced stage and high mortality of gynecological cancer?
Andersen CL; Eskelund CW; Siersma VD; Felding P; Lind B; Palmblad J; Bjerrum OW; Friis S; Hasselbalch HC; de Fine Olivarius N
Gynecol Oncol; 2015 Nov; 139(2):312-8. PubMed ID: 26407478
[No Abstract] [Full Text] [Related]
10. Clinical significance of serum Dkk-3 in patients with gynecological cancer.
Jiang T; Huang L; Wang S; Zhang S
J Obstet Gynaecol Res; 2010 Aug; 36(4):769-73. PubMed ID: 20666943
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer.
Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kulesza-Bronczyk B; Kinalski M; Terlikowski SJ
Eur Cytokine Netw; 2013; 24(3):106-13. PubMed ID: 24197277
[TBL] [Abstract][Full Text] [Related]
12. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer.
Gastl G; Plante M; Finstad CL; Wong GY; Federici MG; Bander NH; Rubin SC
Br J Haematol; 1993 Mar; 83(3):433-41. PubMed ID: 8485049
[TBL] [Abstract][Full Text] [Related]
13. Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies.
Suzuki M; Ohwada M; Sato I; Nagatomo M
Oncology; 1995; 52(2):128-33. PubMed ID: 7854772
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of serum sialosyl-Tn antigen levels in comparison with CA 125 levels in gynecologic cancers.
Ryuko K; Iwanari O; Nakayama S; Iida K; Kitao M
Cancer; 1992 May; 69(9):2368-78. PubMed ID: 1562985
[TBL] [Abstract][Full Text] [Related]
15. Serum evaluation of interleukin 6 in ovarian cancer patients.
Tempfer C; Zeisler H; Sliutz G; Haeusler G; Hanzal E; Kainz C
Gynecol Oncol; 1997 Jul; 66(1):27-30. PubMed ID: 9234916
[TBL] [Abstract][Full Text] [Related]
16. Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors.
Punnonen R; Teisala K; Kuoppala T; Bennett B; Punnonen J
Cancer; 1998 Aug; 83(4):788-96. PubMed ID: 9708947
[TBL] [Abstract][Full Text] [Related]
17. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer.
Berek JS; Chung C; Kaldi K; Watson JM; Knox RM; Martínez-Maza O
Am J Obstet Gynecol; 1991 Apr; 164(4):1038-42; discussion 1042-3. PubMed ID: 2014824
[TBL] [Abstract][Full Text] [Related]
18. Elevation of serum interleukin-1 receptor antagonist levels in women with gynaecological cancers.
Fujiwaki R; Hata T; Miyazaki K; Kawamura T; Inada K
Br J Obstet Gynaecol; 1997 Dec; 104(12):1407-8. PubMed ID: 9422021
[TBL] [Abstract][Full Text] [Related]
19. Serum interleukin-6 levels in uterine malignancies. Preliminary data.
Ferdeghini M; Gadducci A; Prontera C; Bonuccelli A; Annicchiarico C; Fanucchi A; Facchini V; Bianchi R
Anticancer Res; 1994; 14(2B):735-7. PubMed ID: 8010733
[TBL] [Abstract][Full Text] [Related]
20. [Significantly increased interleukin-1A and interleukin-1 soluble type II receptor levels in women with ovarian cancer].
Kondera-Anasz Z; Mielczarek-Palacz A; Switała J
Ginekol Pol; 2003 Sep; 74(9):761-6. PubMed ID: 14674121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
